The serotonin transporter (SERT) is functionally regulated via membrane trafficking. Our previous studies have demonstrated that the SERT C-terminal deletion mutant (SERTΔCT) showed a robust decrease in its membrane trafficking and was retained in the endoplasmic reticulum (ER), suggesting that SERTΔCT is an unfolded protein that may cause ER stress. The Sigma-1 receptor (SigR1) has been reported to attenuate ER stress via its chaperone activity. In this study, we investigated the effects of SKF-10047, a prototype SigR1 agonist, on the membrane trafficking and uptake activity of SERT and SERTΔCT expressed in COS-7 cells. Twenty-four hours of SKF-10047 treatment (> 200μM) accelerated SERT membrane trafficking and robustly upregulated SERT CT activity.
Introduction
The serotonin transporter (SERT) terminates serotonergic neural transmission by reuptaking serotonin (5-HT) into presynaptic terminals in the central nervous system (1, 2) . SERT is a well-known target of antidepressants and drugs of abuse (3) (4) (5) . Therefore, SERT is thought to be involved in the pathogenic mechanisms underlying mood disorders, including depression and drug addiction (3, (6) (7) (8) .
In addition, a SERT polymorphism in the promoter region is involved in vulnerability to stress and anxiety traits (9, 10) . Previous reports revealed that missense mutations of the SERT gene were found in multiple families susceptible to autism (6) (7) (8) . These findings emphasize that SERT is a key molecule that is widely related to various neuropsychiatric disorders, including autism, mood disorders, anxiety disorders, and other stress-related diseases. Therefore, the understanding of the SERT regulation mechanism may pave the way for the development of therapeutic strategies for these psychiatric diseases.
Membrane proteins, including SERT, are commonly glycosylated and folded in the endoplasmic reticulum (ER) after translation from mRNA and then transferred to the plasma membrane through the Golgi apparatus. SERT has two putative glycosylation sites in its second extracellular loop, which are first immaturely glycosylated by mannose (11). Then, SERT becomes a maturely glycosylated protein in the Golgi apparatus, followed by its trafficking to the plasma membrane (12) (13) (14) . We examined the properties of the SERT C-terminal-deleted mutant (SERT CT) to clarify M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT cells expressing SERT CT (17) .
Accumulating recent evidence has demonstrated that the SERT C-terminus contains signal peptides that promote the trafficking of SERT from the ER to the Golgi apparatus (15) . To elucidate the physiological and clinical significance of SERT regulation via membrane trafficking and glycosylation, we focused on ER stress. We examined the effect of ER stress on SERT function.
When ER stress is induced by a proteasome inhibitor, SERT membrane trafficking and uptake activity were decreased (17) . On the other hand, 4-phenylbutyric acid (4-PBA), a chemical chaperone that functions as ER stress relief, promotes SERT membrane trafficking and uptake activity (18) .
The Sigma 1 receptor (SigR1), which is mainly expressed in the ER, has diverse functions.
Recent reports demonstrated that SigR-1A exerts neuroprotective effects by acting as a molecular chaperone (19) (20) (21) (22) (23) . The chaperone activity of SigR-1A is thought to be exerted by the dissociation of GRP78/BiP (binding immunoglobulin protein), a binding molecular chaperone of SigR-1A at its C-terminus. SigR-1A agonists promote the chaperone activity of SigR-1A by detaching GRP78 / BiP from SigR-1A, while antagonists inhibit this process. (24) Based on these findings, we investigated the effect of Sigma receptor ligands on SERT function to clarify the regulatory mechanism of SERT function via membrane trafficking. Here, we reported that SKF-10047, a prototype SigR1 agonist, significantly increased the uptake activity of SERT CT, the effects of which did not depend on the action of SigR1. This unique effect of SKF-10047 on the unfolded protein SERT CT may be useful for improving various pathophysiologies caused by ER stress.
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Materials and Methods
Materials
An anti-DYKDDDDK tag (anti-FLAG) mouse monoclonal antibody was purchased from Wako Pure Chemical Industries Ltd. (Osaka, Japan). An anti-Sigma receptor goat polyclonal antibody was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). An anti-Syntaxin3 rabbit polyclonal antibody was purchased from Alomone labs. (Jerusalem, Israel). An anti-serotonin rabbit polyclonal antibody was purchased from Sigma-Aldrich (St Louis, MA, USA). An Alexa-conjugated anti-t IgG antibodies were purchased from Molecular Probe (Eugene, OR, USA). SKF-10047, NE-100 and PRE-084 were purchased from Tocris Bioscience (Bristol, UK). 
Cell culture and transfection
A plasmid that can express FLAG-tagged rat SERT in mammalian cells was constructed as described previously (25) . The plasmid is designated here as pFLAG-SERT. A plasmid that can express a C-terminus-deleted form of SERT was constructed as described previously (17) . This plasmid is designated here as pFLAG-SERT CT. COS-7 cells were obtained from the Riken Cell Bank (Tsukuba, Japan). AD293 cells, derived from the parental 293 cell line, were obtained from Agilent Technologies (Santa Clara, CA, USA). COS-7 and AD293 cells were cultured in DMEM supplemented with heat-inactivated FBS (10%), penicillin (100 units/ml) and streptomycin (100 g/ml).
For electroporation, various plasmids were transfected into COS-7 or AD293 cells using an NEPA21 electroporator (NEPA GENE, Chiba, Japan) according to the protocol recommended by the M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT supplier. Briefly, 10 g of plasmids were transfected into 2×10 6 COS-7 or AD293 cells, and transfected cells were seeded into appropriate culture dishes.
Generation of SigR1 knockdown cells
A plasmid containing target short hairpin sequences for SigR1 (SigR1 shRNA plasmid) was purchased from Origene (Rockville, MD, USA). The target shRNA sequence was GAGTATGTGCTGCTCTTCGGCACCGCCTT. To generate stable SigR1 knockdown AD293 cells, the SigR1 shRNA plasmid was transfected into cells by electroporation as described above. The transfected cells were diluted to approximately 100-500 cells/ml, seeded on the cultured dished and continuously cultured in the presence of puromycin (2 ng/ml). The cell colonies, which were grown from single cells, were picked 7-10 days after transfection. These cell colonies were continuously cultured in the presence of puromycin and were certified as stable SigR1 knockdown cells after the expression level of SigR1 was validated by western blotting.
To generate cells with transient knockdown of SigR1, the SigR1 shRNA plasmid was transfected into COS-7 cells concomitantly with pFLAG-SERT or pFLAG-SERT CT. Most of the analyses were performed two days after transfection.
For generating STX3 overexpressing cells, a plasmid that can express Myc-DDK-tagged human STX3 isoform A (pMyc-DDK-STX3) was purchased from Origene. Five μg of pMyc-DDK-STX3 was also simultaneously transfected into COS-7 cells with pFLAG-SERT CT by electroporation.
5-HT-Uptake Assay
For the measurement of 5-HT uptake via wild-type SERT-expressing cells using a fluorescent substrate-based method, we used a Neurotransmitter Transporter Uptake Assay kit from Molecular Devices Corporation as previously described (26). In brief, the fluorescence of the substrate incorporated into cells was measured using a high-content screening microscope, Opera Phenix (PerkinElmer, Waltham, MA, USA). The fluorescence intensity per cell 45 min after the application of substrates was determined as the SERT uptake activity. For the [ 3 H] 5-HT uptake assay of SERT CT-transfected COS-7 cells were carried out 48 h after transfection as previously described (17, 18, (26) (27) (28) .
The drugs were applied to culture medium 24 h after the transfection, and the cells were incubated for another 24 h until the uptake assay was performed.
Western blotting analysis
Western blotting was carried out as previously described (17, 18, (26) (27) (28) . In brief, the cell lysate sample (20 -50 g protein) was electrophoretically separated by 10% SDS-PAGE and transferred onto polyvinylidene difluoride (PVDF) filters (Millipore). The PVDF filters were incubated with the anti-DYKDDDDK-tag mouse monoclonal antibody (diluted 1:1000), anti-Sigma receptor-goat polyclonal antibody (diluted 1:500) or anti-Syntaxin3-rabbit polyclonal antibody (diluted 1:500) for M A N U S C R I P T
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Triton X-100), the filters were incubated with horseradish peroxidase-conjugated anti-mouse or rabbit IgG antibody (diluted 1:10,000) for > 1 h at room temperature. The immunoreactive bands were visualized with a chemiluminescence detection kit (Chemi-Lumi One, Nacalai Tesque). The band densities were measured with a luminescent image analyzer (EZ-Capture MG; ATTO).
Immunocytochemistry
Immunocytochemistry was carried out for FLAG-SERT-or FLAG-SERTΔCT-expressing COS-7 cells as previously described (17, 18, 28) . For immunostaining of FLAG-SERT, the primary and secondary antibodies used were the anti-DYKDDDDK tag mouse monoclonal antibody (WAKO, 
Gene microarray analysis
We extracted the total RNA from the AD293 cell lines that were treated with /without 200 μM SKF-10047 for 24 h using an RNeasy mini kit (Qiagen, Hilden, Germany). The obtained RNAs were labeled, hybridized, washed, scanned and digitized by Toray Industries Inc., Tokyo, Japan.
Then, the detected signals for each gene were normalized by the global normalization method (the median of the detected signal intensity was adjusted to 25). 
Measurement of chaperone activity using a-lactalbumin aggregates
Statistical analysis
Data analysis was performed, and statistics were obtained using Prism 4 software (GraphPad Software, San Diego, CA). Statistical significance was determined by Student's t-tests or one-way ANOVA followed by Dunnett's post-test. If the P value was less than 0.05 (P<0.05), the difference was considered significant.
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Results
Effects of the SigR1 ligand SKF-10047 on the uptake activity of SERT
To elucidate the effects of SKF-10047 on the uptake activity of SERT, we transfected FLAG-SERT or FLAG-SERT CT cDNA into COS-7 cells. Twenty-four hours after the transfection, we treated the cells with SKF-10047 (0 -500 μM), and then, 24 h later, we performed the 5-HT uptake assay.
SKF-10047 at 500 μM significantly increased the uptake activity of wild-type SERT (Fig. 1A ).
Next, we examined the effects of SKF-10047 on the uptake activity of SERT CT. Our previous studies revealed that the activity of SERT CT was reduced to approximately one tenth of that of wild type (17, 18) . As shown in Fig. 1B , SKF-10047 significantly and prominently increased the uptake activity of SERT CT in a dose-dependent manner.
The 5-HT uptake via wild-type SERT and SERT CT was immunohistochemically evaluated using an anti-5-HT antibody. In wild-type SERT-expressing cells, incorporated 5-HT was clearly observed as green fluorescence in the acquired images (Fig. 1C ). This immunoreactivity was not observed in the presence of 10 M fluvoxamine, a SERT inhibitor, indicating that the green fluorescence correspond to 5-HT, which was incorporated into cells via SERT (Fig. 1C ).
SKF-10047 did not markedly affect the fluorescence intensity of incorporated serotonin in wild-type SERT-expressing cells. In contrast, in the SERT CT-expressing cells, SKF-10047 appeared to increase the amount of incorporated 5-HT in a dose-dependent manner.
Effects of SKF-10047 on the protein expression and glycosylation of SERT
To elucidate the effects of SKF-10047 on the protein expression and glycosylation of SERT, western blotting analysis was performed on SKF 10047-treated cells expressing FLAG-SERT or
Our previous study clarified that the SERT protein was recognized as multiple bands due to differences in glycosylated modification (17, 18) . Based on our previous analyses using endoglycosidase, the band with a molecular size of approximately 80 kDa (arrowhead) corresponds to the functional and maturely glycosylated SERT that has gone through the Golgi apparatus, and the band with a molecular size of approximately 63 kDa (arrow) corresponds to the high-mannose-type immaturely glycosylated SERT in the ER ( Fig. 2A ). In addition, bands larger than 100 kDa were considered to be dimers of immaturely glycosylated SERT.
In the cells expressing wild-type SERT, the expression level of mature SERT was tended to be increased by SKF-10047, while that of immature SERT was significantly decreased (Supplemental Fig. 1A and 1B) . The total expression level of mature and immature SERT was not influenced by the drug (Supplemental Fig. 1C ). The expression ratio of mature SERT to immature SERT was evaluated as an index of membrane trafficking and glycosylated modification of SERT ( Fig. 2A ). SKF-10047 significantly increased the ratio in a dose-dependent manner, suggesting that SKF-10047 increases the expression of mature SERT and decreases that of immature SERT by promoting its membrane trafficking.
On the other hand, our previous studies revealed that maturely glycosylated SERT CT was scarcely observed, and most SERT CT was recognized as the immaturely glycosylated form (17, 18) . In the cells expressing SERT CT, SKF-10047 significantly decreased the expression of immaturely glycosylated SERT in a dose-dependent manner (Fig. 2B ).
Effects of SKF-10047 on the uptake activity of SERT CT in SigR1 knockdown cells
To elucidate whether the robust incremental effect of SKF-10047 on the uptake activity of SERT CT, as shown in Fig. 1 , was mediated through SigR1, we generated SigR1 knockdown M A N U S C R I P T
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AD293 cells and COS-7 cells using a shRNA plasmid targeting SigR1.
First, we validated the level of shRNA-induced SigR1 knockdown. The SigR1 shRNA reduced SigR1 expression by 53% and 56% in COS-7 cells and AD293 cells, respectively, compared to the expression in mock-transfected control cells (Fig. 3A) . We compared the effects of SKF-10047 on the uptake activity of SERT CT between mock-transfected cells and SigR1 knockdown cells. In COS-7 cells, the increase in uptake activity of SERT CT caused by SKF-10047 (200 μM) was similar in SigR1 knockdown cells and mock-transfected cells (Fig. 3B ). We performed the same studies using AD293 cells. The increase in uptake activity of SERT CT caused by SKF-10047 (0-500 μM) was not significantly different between SigR1 knockdown cells and mock-transfected cells (Fig. 3C ). These results suggest that SKF-10047 did not exert its facilitatory effects on SERT CT function through SigR1.
We also examined whether the activity of wild-type SERT is affected by the knockdown of SigR1. We performed [ 3 H] 5-HT uptake assay instead of fluorescent substrate-based method for the reason as described figure legends (Supplemental Fig. 2 ). The knockdown of SigR1 did not affect the increasing tendency of uptake activity of wild-type SERT by SKF-10047 at 500μM (Supplemental Fig. 2 ).
To ascertain whether SKF-10047 acted directly on SERT CT as a chemical chaperone, we evaluated the chaperone activity of SKF-10047 in vitro using an α-lactalbumin aggregate assay. As shown in Supplemental Fig. 3 , SKF-10047 did not exhibit any chaperone activity in vitro.
Effects of other SigR1 ligands on the uptake activity of SERT CT
Because SKF-10047, a prototype SigR1 agonist, possibly modified the function of SERT independent of its effect on SigR1, we investigated the effects of other sigma receptor ligands on the 5-HT uptake activity of SERT CT.
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PRE-084, which has higher specificity for SigR1 than does SKF-10047 (19, 23, 30) , did not affect the uptake activity of wild-type SERT or SERT CT at the concentration of 0 to 10 M (Supplemental Fig. 4 ). Among the possible SigR1 ligands investigated in this study, pentazocine, NE-100, and haloperidol increased the activity of SERT CT (Supplemental Fig. 5A ). However, the effect of these drugs on SERT CT uptake activity was not affected by SigR1 knockdown (Supplemental Fig. 5B ).
cDNA array analysis to determine the underlying mechanism by which SKF-10047 affects the function of SERT and SERT CT
To clarify the underlying mechanism by which SKF-10047 affects SERT and SERT CT, we comprehensively examined the difference in mRNA expression between the control and cells treated with 200 μM SKF-10047 for 24 h using a cDNA array. The results are shown in Supplemental Table1.
We focused on Syntaxin3 (STX3) as the possible factor affecting the function of SERT via its membrane trafficking. STX3, a member of the SNARE (soluble NSF attachment protein receptor) complex, is known to be involved in endocytosis, thereby regulating the plasma membrane expression of proteins such as cystic fibrosis transmembrane regulator (CFTR) (31, 32) . Therefore, we examined the effect of SKF-10047 on the protein expression of STX3. STX3 was recognized as two bands, corresponding to isoform A and B, main transcripts produced by alternative splicing (https://www.uniprot.org/uniprot/Q13277, Fig. 4 ) In agreement with the results of the cDNA array, 48 h of treatment with SKF-10047 significantly increased the protein levels of both isoforms of STX3 in a dose-dependent manner (Fig. 4 ).
Effects of SKF-10047 on the uptake activity of SERT CT in syntaxin3 (STX3) knockdown or M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT overexpressing cells
To elucidate the involvement of STX3 in the exertion of SKF-10047 effects on SERTΔCT, we investigated whether the incremental effects of SKF-10047 on SERTΔCT was affected by the knockdown or overexpression of STX3. We validated the level of STX3 by the siRNA-induced knockdown and STX3 overexpression by pMyc-DDK-STX3 transfection. The STX3-siRNA #1 and #2 reduced the expression of STX3 isoform A by 54% and 53% in COS-7 cells, compared to the expression in control siRNA-transfected cells (Fig. 5A, upper) . Myc-DDK-tagged STX3 was recognized by immunoblotting for STX3, in addition to endogenous STX3 isoforms (Fig 5A, lower) .
The knockdown of STX3 did not exhibit any influence on the effects of SKF-10047 on the uptake activity of SERTΔCT (Fig. 5B) . In contrast, SKF-10047 further increased the SERTΔCT uptake activity in STX3-overexpressing cells compared to that in mock-transfected cells (Fig. 5C ). These results lead to the possible involvement of STX3 in the exertion of SKF-10047-induced incremental effects on SERTΔCT.
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Discussion
The purpose of this study was to clarify the regulatory mechanism of SERT function by examining the influence of SigR1 ligands on SERT function. SERT uptake activity is thought to be regulated by membrane trafficking (17) . SERT activity is decreased when the SERT protein is retained in the ER by the addition of mutations to the SERT C-terminus or by chemical treatment that impairs its membrane trafficking, such as treatment with brefeldin A or proteasome inhibitors (17, 18) . In contrast, chemical chaperones, including 4-PBA, promote the membrane trafficking of SERT from the ER to the plasma membrane, thereby upregulating SERT function (18) .
SigR1 is known to exist in the ER and exert chaperone activity when agonistic ligands bind to this receptor (19) (20) (21) (22) (23) . Therefore, we predicted that SigR1 and its ligand affect the function of SERT.
First, we examined the effects of SKF-10047, a prototype SigR1 agonist, on SERT membrane trafficking and uptake activity. As shown in Fig. 1 , for both wild-type SERT and C-terminus-deleted mutant (SERT CT), SKF-10047 significantly increased SERT uptake activity. Interestingly, SKF-10047 prominently and robustly increased the uptake activity of SERT CT in a dose-dependent manner. These effects of SKF-10047 on SERT and SERT CT were in agreement with the results observed in our previous study (26). SERT CT was previously found to be retained in the ER as an unfolded protein (18, 26); therefore, these results revealed that SKF-10047 exerted more prominent effects on unfolded SERT than on wild-type SERT.
Next, we performed western blotting analysis to investigate the effects of SKF-10047 on protein expression and glycosylation. In cells expressing wild-type SERT, SKF-10047 decreased the expression of the immaturely glycosylated SERT and increased the expression of the maturely glycosylated SERT, suggesting that SKF-10047 could increase the uptake activity of wild-type SERT by accelerating the trafficking of immature glycosylated SERT in the ER to the plasma membrane.
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In contrast, in cells expressing SERT CT, SKF-10047 clearly decreased the expression of the immaturely glycosylated SERT; however, whether the drug increased the expression of the maturely glycosylated SERT was not apparent because this form of SERT was scarcely observed in SERT CT -expressing cells. Nevertheless, SKF-10047 significantly increased the uptake activity of SERT CT.
These results were coincident with our previous report showing that the chemical chaperone 4-PBA increased the uptake activity of SERT CT without the clear appearance of maturely glycosylated SERT (18) . The reason why an increase in maturely glycosylated SERT was not observed instead of the observed decrease in immaturely glycosylated SERT is unknown. One possibility is that the expression of maturely glycosylated SERT may be lower than the level detectable by western blotting. Alternatively, SERTΔCT may remain in the immaturely glycosylated form when it is transported to the plasma membrane, and SERTΔCT may function as an incomplete transporter. SigR1 was thought to exert its chaperone activity by the binding of SigR1 agonists to the receptor, the effects of which are in turn inhibited by SigR1 antagonists. To elucidate whether the incremental effect of SKF-10047 on the uptake activity of SERT CT was mediated through SigR1, we investigated the effect of this drug in SigR1 knockdown cells. However, the incremental effects of SKF-10047 on the uptake activity of SERT CT remained in SigR1 knockdown cells, suggesting that these effects of SKF-10047 were not through actions on SigR1. This idea was supported by the result M A N U S C R I P T
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that PRE-084, which has higher specificity to SigR1 than does SKF-10047 (19, 23) , did not affect the uptake activity of SERT CT. Based on these findings, we predicted that SKF-10047 increases the uptake activity of SERT CT by a SigR1-independent mechanism. Alternatively, SKF-10047 itself may have chemical chaperone activity, although not plausible based on the findings in Supplemental Fig. 3 .
Therefore, to clarify the novel mechanism underlying the effects of SKF-10047 on SERT CT, we compared the difference in gene expression between SKF-10047-treated and control cells using a cDNA array. First, we chose the genes that showed sufficient endogenous expression with a global normalization value of more than 10. Next, we selected the genes that showed more than a two-fold change in expression in SKF-10047-treated cells compared to that in control cells (Supplemental Table 1 ). Among these, we focused on Syntaxin3 (STX3) as a gene that is related to membrane trafficking. STX3 is one of the SNARE proteins that induces exocytosis and facilitates the expression of membrane proteins, including transporters and receptors, to the plasma membrane (31, 32) . Indeed, the plasma membrane expression of cystic fibrosis transmembrane regulator (CFTR), a membrane transporter, is known to be regulated by STX3. In addition, STX3 binds to SERT and regulates its function in CaCo-2 cells, an intestinal cell line (33) . Although it is not clear whether SKF-10047 up-regulated the STX3 expression via SigR1-dependent mechanism or not at present, SKF-10047 increased the protein expression of STX3, as shown in Fig. 4 . STX3 may be a candidate molecule that is involved in the novel mechanism of SKF-10047 on SERT.
To elucidate whether STX3 is involved in the exertion of SKF-10047 effects on SERTΔCT, we generated the STX3-knockdown or STX3-overexpressing cells, and investigated whether the knockdown and overexpression of STX3 affects the incremental effects of SKF-10047 on SERTΔCT uptake activity. As shown Fig.5 , in STX3-overexpressing cells, not STX3-knockdown cells, SKF-10047 further increased the uptake activity of SERTΔCT, suggesting that STX3 is possibly and M A N U S C R I P T
involved in the SKF-10047 action on SERTΔCT via some mechanism. Further investigation is necessary to confirm the underlying mechanism by which STX3 could regulate the function of wild-type SERT or SERTΔCT.
Interestingly, SigR1 ligands other than SKF-1004, such as NE-100, pentazocine and haloperidol, increased the uptake activity of SERT CT, regardless of whether these ligands were agonists or antagonists. Furthermore, the effects of these drugs on SERT CT were retained in SigR1 knockdown cells. These findings lead to the possibility that SigR1 ligands other than just SKF-10047, which are thought to exert their effect through SigR1, regulate the function of membrane proteins through a novel mechanism. Among the ligands of SigR1, including SKF-10047, there might be a useful drug that can relieve ER stress.
In conclusion, SKF-10047 is a candidate drug for the relief of ER stress, which is caused by the accumulation of unfolded membrane proteins. Effects of SKF-10047 on the uptake activity of wild-type (WT) SERT or SERT CT.
A: Effects of SKF-10047 on the uptake activity of WT SERT.
In the cells expressing wild-type SERT, we measured the uptake of fluorescent SERT substrate per cell as the 5-HT uptake activity. We evaluated the uptake activity using the Neurotransmitter Transporter Uptake Assay kit as described in the Materials and Methods. SKF-10047 (500 μM) significantly increased the uptake activity of WT SERT (**P<0.05, n=9, one-way ANOVA with Dunnett's post-test).
B: Effects of SKF-10047 on the uptake activity of SERT CT.
We examined the effects of SKF-10047 on the uptake activity of SERT CT using a [ 3 H] 5-HT-uptake assay as described in Materials and Methods. SKF-10047 significantly and prominently increased the uptake activity of SERT CT in a dose-dependent manner (*P<0.05, n=4, one-way ANOVA with Dunnett's post-test).
C: Immunocytochemical analysis for evaluating 5-HT uptake via SERT.
After FLAG-SERT-or FLAG-SERT CT-expressing cells were treated with SKF-10047 for 24 h, the cells were treated with 1 M serotonin for 15 min, and then fixed with 4% paraformaldehyde for later immunohistochemical procedures. Fixed cells were first reacted with the anti-FLAG antibody for SERT, followed by the anti-5-HT antibody for detecting the incorporated 5-HT. Cells were further visualized in red for SERT and green for 5-HT with Alexa 546-conjugated anti-mouse IgG or Alexa 488-conjugated anti-rabbit IgG, respectively.
In the cells expressing WT SERT, SKF-10047 did not markedly affect the fluorescence intensity of 
Fig. 3
Effects of SKF-10047 on the uptake activity of SERT CT in SigR1 knockdown cells. COS-7 cells were transiently transfected with SigR1 shRNA, and AD293 cells were stably transformed with the shRNA. We used cells transfected with a mock vector that did not contain shRNA as control cells. 
Fig. 4
Effects of SKF-10047 on the protein expression of Syntaxin3 (STX3).
Syntaxin3 consists of some isoforms, produced by alternative splicing 
Fig. 5
Influence of knockdown or overexpression of Syntaxin3 on the incremental effects of SKF-10047 on the SERTΔCT uptake activity.
We examined the effects of SKF-10047 on the SERTΔCT uptake activity in STX3-konockdown or STX3-overexpressing COS-7cells, and compared the increasing rate in these cells to that in control cells.
A Fig. 2A was measured as the total expression level of WT SERT. The level was not affected by SKF-10047 (n=4, ns, one-way ANOVA with Dunnett's post-test).
Supplemental Figure 2
Effects of SKF-10047 on the uptake activity of wild-type SERT in SigR1 knockdown cells.
Instead of Neurotransmitter Transporter Uptake Assay kit, we used a [ 3 H] 5-HT-uptake assay for this experiment because a SigR1 shRNA plasmid simultaneously expresses Green fluorescent protein (GFP). Of note, our previous study demonstrated that SKF-10047 at 500μM tended to increase the uptake activity of WT SERT without statistical significance when we used a [ 3 H] 5-HT-uptake assay (26), which is incomparable to the result shown in Fig. 1A . In both mock-transfected and SigR1 knockdown cells, 500μM SKF-10047 slightly increased the WT SERT uptake activity, which is consistent with our previous study (26). There was no significant difference in the effects of SKF-10047on the SERT activity between mock-transfected and SigR1 knockdown cells (n=4, ns, unpaired t-test).
Supplemental Figure 3
The chaperone activity of SKF-10047 was evaluated using α-lactalbumin aggregates induced by denatured BSA. Aggregation was measured by the absorbance at 490 nm.
No significant change in absorbance was observed between the control and SKF-10047-treated groups, indicating that SKF-10047 did not exhibit chaperone activity.
Supplemental Figure 4
Effects of PRE-084 on the uptake activity of WT SERT and SERT CT.
PRE-084, which has higher specificity to SigR1 than does SKF-10047, did not affect the uptake 
Supplemental Figure5
Some SigR1 ligands increased the uptake activity of SERT, regardless of whether the ligand was an agonist or an antagonist. Supplemental Table 1 cDNA array results showed several genes that were upregulated by the treatment of AD293 cells with 200 μM SKF-10047 for 24 h.
We comprehensively examined the difference in mRNA expression between the control cells and the cells treated with 200 μM SKF-10047 for 24 h. The table shows the list of genes that have a global normalization value of more than 10 and an incremental ratio of more than 2. We focused on 
